Mon - Fri 09:00-17:00
Follow Us on Social


The Problem
The Toxicity of Chemotherapy Pre-Conditioning

Cell-based immunotherapy requires toxic chemotherapy pre-conditioning to prevent the cells from accumulating in the spleen. The pre-conditioning keeps the cells in the blood stream where they can find and kill the cancer cells, and allows long-term engraftment of the cell therapy. Unfortunately, this necessary pre-conditioning comes at a price with toxic, sometimes life-threatening, side effects such as: Nausea and Vomiting, Mucositis, Leukopenia, Thrombocytopenia, Granulocytopenia, Neutropenia, Cardiotoxicity, Infections, Pneumonia, Anemia, and Hair Loss.

AVM0703 for Immuno-Oncology
AVM0703 non toxic replacement for chemotherapy preconditioning for CAR-T/NK/TCR/TAC and other cell-based immunotherapies.

AVM0703 is used in combination with stem cell-based therapies to significantly enhance stem cell tumor targeting and engraftment. AVM0703 is ready for Phase 2 clinical trials in combination with cell-based immunotherapies.

AVM0703 GLP product material is currently available for animal studies, and GMP product material for human clinical trials will be ready in Q4.2017.


The market for CAR-T cell-based therapies is expected to grow to $30 billion USD by 2030. There are currently 300 CAR-T cell-based therapies in clinical pipeline with most of them in Phase-I and Phase-I/II clinical trials.  Any clinical advantage is critical in this hyper-competitive market. Preconditioning has been shown to be required for immunotherapy effectiveness and long-term engraftment. However, as many as one in five Multiple Myeloma patients cannot tolerate the toxic chemotherapy pre-conditioning and do not qualify for potentially life-saving CAR-T or NK treatments.

Replacing toxic chemotherapy with an equally effective non-toxic alternative, AVM0703, will make the licensee’s Car-T/NK the treatment of choice and expand the market to include patients too frail to tolerate chemotherapy. PlenaStem™ has the potential to reduce the risk of cytokine release syndrome and graft rejection due to its distinct lymphodepletion activity.

Our R&D Pipeline

Discovery & Lead ValidationComplete
Optimization & FormulationComplete
Efficacy & Safety - In Vitro & In VivoComplete
Partnering Negotiation In Process